Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), is pleased to
announce the company has secured delivery of the delivery of first
production batch Personal Protective Equipment (“PPE”) from the a
supply agreement entered into the last quarter of 2020 with 24
Clean Energy (the “
Supplier”), a manufacturer and
distributor of high-end medical grade nitrile gloves. Relevium has
also obtained the exclusive North American rights to market the
“
DI-Line” brand of medical grade gloves, a much
needed and sought-after PPE product.
This initial order of 500,000 boxes, each box
containing a 100-unit count, was secured at a cost of just over CAD
$5 million, with funds being paid in advance at the time of order.
The supplier has finished the first production run and the gloves
are expected to arrive at the port of Los Angeles during the third
week of April. The Company will deliver the gloves to its customers
in the US in conjunction with its Canadian distribution partners.
The Company expects revenues from the 500,000 boxes to be of a
total transactional value of between CAD $8 and $10 million.
According to market research company Grand View,
in 2019, prior to the pandemic, the global nitrile gloves market
size was valued at USD 3.12 Billion, with an expected compounded
annual growth rate (CAGR) of 14.1% from 2020 to 2027, not including
the effect of the current pandemic. Rising awareness regarding the
benefits of the PPE product in healthcare facilities, coupled with
the recent COVID-19 pandemic, are expected to accelerate the
long-term demand, and in particular as health agencies in Europe
review proposals for making the use of nitrile gloves mandatory in
the services and institutional industries as well.
Aurelio Useche, CEO of Relevium stated, “We see
a long-term incremental demand for health care PPE and related
products, a natural fit to our existing core, which will be
channeled in conjunction with the H-Source Platform. We proactively
capture the opportunity created by a major gap in the demand and
supply of this commodity leaving users looking for a stable supply
chain. We expect the imbalance to remain strong throughout 2021 and
prices to remain elevated”.
Mr. Useche further comments: “We have now
secured direct access to PPE manufactures & suppliers, which
has established significant credibility with our valued customers.
By collaborating with our trusted partner H-Source Holdings (TSXV:
HSI), we can now deploy an entire end-to-end solution, including
procurement, logistics & supply-chain delivery, all backed by
block-chain technology. This provides Relevium a significant
advantage for existing and future opportunities in the PPE /
medical sectors, both in North America and globally”.
About Relevium
TechnologiesRelevium is a publicly traded Company that
operates in the health and wellness industry, including
cannabinoids, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and cannabinoids. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical Company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory
approvals.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the proposed business developments may not occur as planned; the
timing and receipt of requisite approvals and failure to raise
sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024